EUVIMEDDescubrir EUVIMED
Crossref

Beyond Continuation: Early Sodium–Glucose Cotransporter 2 Inhibitor Initiation After Transcatheter Aortic Valve Implantation

Ivana Jurin, Daniel Unić, Hrvoje Jurin, Irzal Hadžibegović

Catheterization and Cardiovascular Interventions · 2026-11-20

DOI: 10.1002/ccd.71037 ↗

At a glance

Journal article in Catheterization and Cardiovascular Interventions, published online on 2026-11-20. Written by Ivana Jurin and 3 co-authors. 6 references.

ResumenDatos bibliográficosCiteRelated studies

Abstract (original language)

Background

Overall sodium–glucose cotransporter 2 (SGLT2) inhibitor use after transcatheter aortic valve implantation (TAVI) combines continuation and new initiation. We characterized these distinct prescribing processes and the clinical profiles accompanying initiation. Aims and Methods This retrospective single‐center registry included 653 patients undergoing TAVI in 2022–2025. Exposure was assessed within 90 days before and 30 days after TAVI using discharge summaries and electronic medical records. The primary measure was initiation among previously untreated patients. Admission and wait‐list N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) measurements were summarized separately.

Results

Early medication status was known in 639 patients; 260 (40.7%) received SGLT2 inhibitors. Among 638 patients with paired records, 184 continued therapy, 76 initiated, eight did not continue, and 370 had no use in either window. Continuation occurred in 184/192 previously treated patients (95.8%), whereas initiation occurred in 76/446 previously untreated patients (17.0%; 95% confidence interval, 13.8–20.8). Initiation was 70/351 (19.9%) in a secondary subgroup with selected clinical risk features, without established trial eligibility. Admission NT‐proBNP was available in 590 patients (90.4%); wait‐list values were available in 356, including 349 with both assessments. Initiators had lower ejection fraction and higher admission NT‐proBNP. Urinary tract infection explained four of eight non‐continuations.

Conclusions

High continuation coexisted with limited new initiation. Transition‐specific reporting clarifies early prescribing and supports individualized reassessment after TAVI, but does not establish treatment effects or the appropriateness of individual non‐prescription decisions.

Cite

APA

Jurin, I., Unić, D., Jurin, H., & Hadžibegović, I. (2026). Beyond Continuation: Early Sodium–Glucose Cotransporter 2 Inhibitor Initiation After Transcatheter Aortic Valve Implantation. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.71037

Vancouver

Jurin I, Unić D, Jurin H, Hadžibegović I. Beyond Continuation: Early Sodium–Glucose Cotransporter 2 Inhibitor Initiation After Transcatheter Aortic Valve Implantation. Catheterization and Cardiovascular Interventions. 2026. doi:10.1002/ccd.71037

BibTeX
@article{Jurin2026,
  author = {Jurin, Ivana and Unić, Daniel and Jurin, Hrvoje and Hadžibegović, Irzal},
  title = {Beyond Continuation: Early Sodium–Glucose Cotransporter 2 Inhibitor Initiation After Transcatheter Aortic Valve Implantation},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2026},
  doi = {10.1002/ccd.71037}
}
Start for free →